Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drugging RAS: Know the enemy
Bjoern Papke, Channing J. Der
Science (2017) Vol. 355, Iss. 6330, pp. 1158-1163
Open Access | Times Cited: 356

Showing 26-50 of 356 citing articles:

Understanding and targeting resistance mechanisms in cancer
Zi‐Ning Lei, Tian Qin, Qiu‐Xu Teng, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 114
Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer
Sarah A. Best, Patrick M. Gubser, Shalini Sethumadhavan, et al.
Cell Metabolism (2022) Vol. 34, Iss. 6, pp. 874-887.e6
Open Access | Times Cited: 105
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 919-926
Open Access | Times Cited: 98
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 41
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access | Times Cited: 2
RAS-mediated oncogenic signaling pathways in human malignancies
Abdul Quaiyoom Khan, Shilpa Kuttikrishnan, Kodappully Sivaraman Siveen, et al.
Seminars in Cancer Biology (2018) Vol. 54, pp. 1-13
Closed Access | Times Cited: 154
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Angelina V. Vaseva, Devon R. Blake, Thomas S.K. Gilbert, et al.
Cancer Cell (2018) Vol. 34, Iss. 5, pp. 807-822.e7
Open Access | Times Cited: 149
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
Rasmus Hansen, Ulf Peters, Anjali Babbar, et al.
Nature Structural & Molecular Biology (2018) Vol. 25, Iss. 6, pp. 454-462
Closed Access | Times Cited: 129
The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2
Joanna Kovalski, Aparna Bhaduri, Ashley Zehnder, et al.
Molecular Cell (2019) Vol. 73, Iss. 4, pp. 830-844.e12
Open Access | Times Cited: 127
RAS mutations in human cancers: Roles in precision medicine
Avaniyapuram Kannan Murugan, Michèle Grieco, Nobuo Tsuchida
Seminars in Cancer Biology (2019) Vol. 59, pp. 23-35
Closed Access | Times Cited: 123
Targeting PP2A in cancer: Combination therapies
Sahar Mazhar, Sarah E. Taylor, Jaya Sangodkar, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2018) Vol. 1866, Iss. 1, pp. 51-63
Open Access | Times Cited: 120
Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release
Chao Kong, Yang Li, Zhengsheng Liu, et al.
ACS Nano (2019) Vol. 13, Iss. 4, pp. 4049-4063
Closed Access | Times Cited: 117
Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
Katherine Chung, Jaffarguriqbal Singh, Lauren Lawres, et al.
Cell (2020) Vol. 181, Iss. 4, pp. 832-847.e18
Open Access | Times Cited: 109
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
Arun M. Unni, Bryant Harbourne, Min Hee Oh, et al.
eLife (2018) Vol. 7
Open Access | Times Cited: 97
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Sen Yu, Chunyu Zhang, Keping Xie
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1875, Iss. 1, pp. 188461-188461
Closed Access | Times Cited: 97
A Combined Morphologic and Molecular Approach to Retrospectively Identify KRAS-Mutated Mesonephric-like Adenocarcinomas of the Endometrium
David L. Kolin, Danielle C. Costigan, Fei Dong, et al.
The American Journal of Surgical Pathology (2018) Vol. 43, Iss. 3, pp. 389-398
Closed Access | Times Cited: 94
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Jay B. Fell, John P. Fischer, Brian R. Baer, et al.
ACS Medicinal Chemistry Letters (2018) Vol. 9, Iss. 12, pp. 1230-1234
Open Access | Times Cited: 93
Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk
Ioanna Ntai, Luca Fornelli, Caroline J. DeHart, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 16, pp. 4140-4145
Open Access | Times Cited: 92
Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins
Alexander J. Martinko, Charles Truillet, Olivier Julien, et al.
eLife (2018) Vol. 7
Open Access | Times Cited: 89
Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium
Raphael Brandt, Thomas Sell, Mareen Lüthen, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 89
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
Irem Ozkan‐Dagliyan, J. Nathaniel Diehl, Samuel D. George, et al.
Cell Reports (2020) Vol. 31, Iss. 11, pp. 107764-107764
Open Access | Times Cited: 88
Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma
Min Kyeong Kim, Sang Myung Woo, Boram Park, et al.
Clinical Chemistry (2018) Vol. 64, Iss. 4, pp. 726-734
Open Access | Times Cited: 85
Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
Sarah A. Best, Sheryl Ding, Ariena Kersbergen, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 84
Deactivation Pathway of Ras GTPase Underlies Conformational Substates as Targets for Drug Design
Shaoyong Lu, Duan Ni, Chengxiang Wang, et al.
ACS Catalysis (2019) Vol. 9, Iss. 8, pp. 7188-7196
Closed Access | Times Cited: 83
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Rita Sulahian, Jason J. Kwon, Katherine H. Walsh, et al.
Cell Reports (2019) Vol. 29, Iss. 1, pp. 118-134.e8
Open Access | Times Cited: 79

Scroll to top